PMEL and melanoma: In a single-arm phase II clinical study, TriMix-DCs, transfected with TriMix and four TAAs (melanoma-associated antigen (MAGE)-A3, MAGE-C2, tyrosinase, or gp100) fused to an MHC class II targeting signal, plus the mAb ipilimumab (blocking the immune checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)) were combined in 39 pretreated advanced melanoma patients (NCT01302496) [37].